Primary Endpoint For Pivotal Phase 3 SENTRY Trial In Myelofibrosis

Karyopharm Therapeutics

31/10/2024 11:33

Oct 31 (Reuters) - Karyopharm Therapeutics Inc  KPTI.O :
    * KARYOPHARM ANNOUNCES FAVORABLE CHANGE IN CO-PRIMARY
ENDPOINT FOR
PIVOTAL PHASE 3 SENTRY TRIAL IN MYELOFIBROSIS
    * KARYOPHARM THERAPEUTICS INC - CO-PRIMARY ENDPOINT CHANGED
TO
ABSOLUTE TOTAL SYMPTOM SCORE (ABS-TSS)
    * KARYOPHARM THERAPEUTICS INC - SPLEEN VOLUME RESPONSE RATE
≥ 35%
(SVR35) REMAINS CO-PRIMARY ENDPOINT
    * KARYOPHARM THERAPEUTICS INC - SENTRY TRIAL SAMPLE SIZE
INCREASED
TO APPROXIMATELY 350 PATIENTS

Source text:  ID:nPnb5Wmj8a 
Further company coverage:  KPTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))